Developer docs
API playgroundTry for free, no card

Search company profiles

Blackstone Multi-Asset Investing

Full company profile

uuid0031857

Namestring
Blackstone Multi-Asset Investing
Legal namestring
Blackstone Inc.
Websiteurl
blackstone.com
Company typeenum
Public
Founded yearint
1985
Descriptiontext

Blackstone Multi-Asset Investing (BXMA) is a core business division of Blackstone Inc. (NYSE: BX) and is described as the world's largest discretionary allocator to hedge funds. Operating within Blackstone's broader $1.3 trillion alternative asset management platform as of March 31, 2026, BXMA provides multi-asset investment solutions spanning hedge funds, private equity, real estate, credit, and infrastructure, with an emphasis on absolute return strategies and cross-asset portfolio construction. The division is led by Senior Managing Director Joe Dowling as Global Head, alongside a senior team including David Ben-Ur (CIO of Absolute Return), Riad Abrahams (Head of Strategy, Risk and Quant Analytics), and other managing directors across New York, Washington DC, and Singapore.

BXMA serves two primary client segments: institutional investors (pensions, endowments, foundations, insurers) and private wealth clients (high-net-worth individuals, family offices, and individual investors served via financial advisors). Distribution occurs through Blackstone's Institutional Client Solutions group, its Private Wealth channel, and its Registered Investment Advisor network, supplemented by educational platforms such as Blackstone University and thought leadership content including Market Views and Pattern Recognition publications. Registered perpetual products — including Blackstone Real Estate Income Trust (BREIT), Blackstone Private Credit Fund (BCRED), and Blackstone Private Multi-Asset Credit and Income Fund (BMACX) — extend institutional-quality alternative strategies to private wealth clients.

BXMA generates revenue through management fees and performance allocations on its multi-asset portfolios, leveraging Blackstone's scale economics. The unit participates in cross-platform deal flow, evidenced by recent co-investments such as participation in Tubulis's €344 million Series C financing and the Athira Pharma lasofoxifene Phase 3 development financing of up to $236 million. Segment-level revenue is not separately disclosed by the publicly traded parent.

Short descriptiontext

Blackstone Multi-Asset Investing (BXMA) is the world's largest discretionary allocator to hedge funds, a core division of Blackstone Inc. providing multi-asset and absolute return strategies to institutional investors, family offices, and high-net-worth individuals globally.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
Markets served

Serves global market

Keyword5 values
multi-asset investing, hedge fund allocation, alternative asset management, absolute return strategies, institutional investment solutions
Industry2 codes
1Business Services (B2B) Growth Equity
CodeFSANACADPrimaryYes
2Securitized Products & Mortgage Credit (RMBS/CMBS/Non-Agency)
CodeFSAHAGADPrimaryNo
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Securities, Commodity Contracts, and Other Financial Investments and Related Activities523
SIC code2 codes
  • Investment Advice6282
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Alternative Asset Management
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 3 records shown
1Blackstone Real Estate Income Trust (BREIT)
Description

A private investment platform focused on income-generating real estate.

blackstone.com
+2 more records
Core offering1 text field

Blackstone Multi-Asset Investing (BXMA) is a division of Blackstone Inc. that serves as the world's largest discretionary allocator to hedge funds, providing multi-asset investment strategies spanning hedge funds, private equity, real estate, credit, and infrastructure. The division builds and manages cross-asset portfolio solutions for institutional clients and private wealth channels, leveraging Blackstone's $1.3 trillion platform scale to source, negotiate, and execute investments.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Blackstone Multi-Asset Investing (BXMA) is one of Blackstone's core business units focused on multi-asset investment strategies. As part of Blackstone's broader alternative asset management platform with over $1.3 trillion in AUM, BXMA operates as a division that oversees and leads multi-asset investment activities, including hedge fund allocation and absolute return strategies. The division is led by Global Head Joe Dowling and includes teams focused on strategy, risk and quant analytics, absolute return platforms, and various investment approaches across global markets.

Product and service1 record
1Blackstone Multi-Asset Investing (BXMA)
CategoryMulti-Asset Investment Management
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Athira Pharma licensed the lasofoxifene Phase 3 development program from Sermonix Pharmaceuticals for metastatic breast cancer candidate, demonstrating BXMA's role in supporting life sciences investments through portfolio companies.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Millennium is a leading multi-strategy hedge fund platform that increasingly offers institutional allocators multi-manager exposures, overlapping with BXMA's allocator business.

TypeBroad incumbent
Description

BlackRock is the world's largest asset manager with a fast-growing alternatives platform and multi-asset strategies, serving many of the same institutional and wealth clients as BXMA.

TypeDirect peer
Description

Man Group runs a multi-asset, multi-strategy hedge fund and discretionary allocator platform (including FRM and AHL), serving institutional clients in much the same way BXMA does.

TypeBroad incumbent
Description

GSAM offers a broad multi-asset and alternatives platform serving institutional and wealth clients; it competes for the same multi-asset mandates and absolute return allocations that BXMA targets.

TypeDirect peer
Description

Bridgewater operates the world's largest hedge fund and runs All Weather and other multi-asset/multi-strategy strategies for institutional clients, directly competing with BXMA's discretionary allocator and absolute return platform.

TypeBroad incumbent
Description

Apollo operates a broad alternatives platform across credit, equity, and real assets with growing multi-asset solutions, directly comparable to Blackstone's and BXMA's institutional offerings.

TypeBroad incumbent
Description

JPMAM offers a broad multi-asset and alternatives platform to institutional and private wealth clients globally, competing with BXMA for institutional mandates and absolute return allocations.

TypeBroad incumbent
Description

KKR is a global alternatives platform with growing multi-strategy and hedge fund allocation capabilities, competing with Blackstone/BXMA for institutional and private wealth alts mandates.

TypeDirect peer
Description

AQR runs systematic, multi-asset absolute return strategies for institutional allocators, overlapping directly with BXMA's absolute return and discretionary allocator mandates.

TypeBroad incumbent
Description

Carlyle is a global alternatives manager with multi-asset capabilities expanding across private wealth, competing with Blackstone's broader platform that BXMA helps distribute.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment11 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Blackstone Multi-Asset Investing

Alternative Asset Managementblackstone.com

Blackstone Multi-Asset Investing (BXMA) is the world's largest discretionary allocator to hedge funds, a core division of Blackstone Inc. providing multi-asset and absolute return strategies to institutional investors, family offices, and high-net-worth individuals globally.

What Blackstone Multi-Asset Investing does

Blackstone Multi-Asset Investing (BXMA) is a core business division of Blackstone Inc. (NYSE: BX) and is described as the world's largest discretionary allocator to hedge funds. Operating within Blackstone's broader $1.3 trillion alternative asset management platform as of March 31, 2026, BXMA provides multi-asset investment solutions spanning hedge funds, private equity, real estate, credit, and infrastructure, with an emphasis on absolute return strategies and cross-asset portfolio construction. The division is led by Senior Managing Director Joe Dowling as Global Head, alongside a senior team including David Ben-Ur (CIO of Absolute Return), Riad Abrahams (Head of Strategy, Risk and Quant Analytics), and other managing directors across New York, Washington DC, and Singapore.

BXMA serves two primary client segments: institutional investors (pensions, endowments, foundations, insurers) and private wealth clients (high-net-worth individuals, family offices, and individual investors served via financial advisors). Distribution occurs through Blackstone's Institutional Client Solutions group, its Private Wealth channel, and its Registered Investment Advisor network, supplemented by educational platforms such as Blackstone University and thought leadership content including Market Views and Pattern Recognition publications. Registered perpetual products — including Blackstone Real Estate Income Trust (BREIT), Blackstone Private Credit Fund (BCRED), and Blackstone Private Multi-Asset Credit and Income Fund (BMACX) — extend institutional-quality alternative strategies to private wealth clients.

BXMA generates revenue through management fees and performance allocations on its multi-asset portfolios, leveraging Blackstone's scale economics. The unit participates in cross-platform deal flow, evidenced by recent co-investments such as participation in Tubulis's €344 million Series C financing and the Athira Pharma lasofoxifene Phase 3 development financing of up to $236 million. Segment-level revenue is not separately disclosed by the publicly traded parent.

Blackstone Multi-Asset Investing firmographics

Firmographics
Name
Blackstone Multi-Asset Investing
Legal name
Blackstone Inc.
Website
https://blackstone.com
Company type
Public
Founded year
1985
Operating status
Operating
Short description
Blackstone Multi-Asset Investing (BXMA) is the world's largest discretionary allocator to hedge funds, a core division of Blackstone Inc. providing multi-asset and absolute return strategies to institutional investors, family offices, and high-net-worth individuals globally.
Ownership category
akta.pro rank

Blackstone Multi-Asset Investing industry classification

Industry
Product category
Alternative Asset Management
NAICS
Portfolio Management and Investment Advice (523940), Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)
SIC
Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)
akta.pro primary industry
Business Services (B2B) Growth Equity (FSANACAD)
akta.pro secondary industry
Securitized Products & Mortgage Credit (RMBS/CMBS/Non-Agency) (FSAHAGAD)

Keywords

  • Multi-asset investing
  • Hedge fund allocation
  • Alternative asset management
  • Absolute return strategies
  • Institutional investment solutions

Blackstone Multi-Asset Investing business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Distribution channels3 records

Marketing channels5 records

Blackstone Multi-Asset Investing product offering

Product offering

Core offering

Blackstone Multi-Asset Investing (BXMA) is a division of Blackstone Inc. that serves as the world's largest discretionary allocator to hedge funds, providing multi-asset investment strategies spanning hedge funds, private equity, real estate, credit, and infrastructure. The division builds and manages cross-asset portfolio solutions for institutional clients and private wealth channels, leveraging Blackstone's $1.3 trillion platform scale to source, negotiate, and execute investments.

Product overview

Blackstone Multi-Asset Investing (BXMA) is one of Blackstone's core business units focused on multi-asset investment strategies. As part of Blackstone's broader alternative asset management platform with over $1.3 trillion in AUM, BXMA operates as a division that oversees and leads multi-asset investment activities, including hedge fund allocation and absolute return strategies. The division is led by Global Head Joe Dowling and includes teams focused on strategy, risk and quant analytics, absolute return platforms, and various investment approaches across global markets.

Differentiator

Problem solved

Functional benefit

Brands

  • Blackstone Real Estate Income Trust (BREIT): A private investment platform focused on income-generating real estate.
  • Blackstone Private Credit Fund (BCRED)
  • Blackstone Private Multi-Asset Credit and Income Fund (BMACX)

Products and services

  • Blackstone Multi-Asset Investing (BXMA)

Companies that use Blackstone Multi-Asset Investing

Customer profile

Segments2 records

Ideal customer profiles2 records

Blackstone Multi-Asset Investing technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Blackstone Multi-Asset Investing partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Sermonix PharmaceuticalscoreStrategic or Co-development Partner · 18 December 2025Athira Pharma licensed the lasofoxifene Phase 3 development program from Sermonix Pharmaceuticals for metastatic breast cancer candidate, demonstrating BXMA's role in supporting life sciences investments through portfolio companies.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Blackstone Multi-Asset Investing competitors and assessment

Company assessment

Direct peers

  • Millennium Management: Millennium is a leading multi-strategy hedge fund platform that increasingly offers institutional allocators multi-manager exposures, overlapping with BXMA's allocator business.
  • Man Group: Man Group runs a multi-asset, multi-strategy hedge fund and discretionary allocator platform (including FRM and AHL), serving institutional clients in much the same way BXMA does.
  • Bridgewater Associates: Bridgewater operates the world's largest hedge fund and runs All Weather and other multi-asset/multi-strategy strategies for institutional clients, directly competing with BXMA's discretionary allocator and absolute return platform.
  • AQR Capital Management: AQR runs systematic, multi-asset absolute return strategies for institutional allocators, overlapping directly with BXMA's absolute return and discretionary allocator mandates.

Broad incumbents

  • BlackRock: BlackRock is the world's largest asset manager with a fast-growing alternatives platform and multi-asset strategies, serving many of the same institutional and wealth clients as BXMA.
  • Goldman Sachs Asset Management: GSAM offers a broad multi-asset and alternatives platform serving institutional and wealth clients; it competes for the same multi-asset mandates and absolute return allocations that BXMA targets.
  • Apollo Global Management: Apollo operates a broad alternatives platform across credit, equity, and real assets with growing multi-asset solutions, directly comparable to Blackstone's and BXMA's institutional offerings.
  • JPMorgan Asset Management: JPMAM offers a broad multi-asset and alternatives platform to institutional and private wealth clients globally, competing with BXMA for institutional mandates and absolute return allocations.
  • KKR & Co. KKR is a global alternatives platform with growing multi-strategy and hedge fund allocation capabilities, competing with Blackstone/BXMA for institutional and private wealth alts mandates.
  • Carlyle Group: Carlyle is a global alternatives manager with multi-asset capabilities expanding across private wealth, competing with Blackstone's broader platform that BXMA helps distribute.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Blackstone Multi-Asset Investing social profiles

Digital presence

Blackstone Multi-Asset Investing financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Blackstone Multi-Asset Investing leadership team

Management profile

Number of profiles

Profiles11 records

Blackstone Multi-Asset Investing subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

Blackstone Multi-Asset Investing funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Blackstone Multi-Asset Investing M&A and investment

M&A and investment

M&A

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blackstone Multi-Asset Investing

What does Blackstone Multi-Asset Investing do?

Blackstone Multi-Asset Investing (BXMA) is a division of Blackstone Inc. that serves as the world's largest discretionary allocator to hedge funds, providing multi-asset investment strategies spanning hedge funds, private equity, real estate, credit, and infrastructure. The division builds and manages cross-asset portfolio solutions for institutional clients and private wealth channels, leveraging Blackstone's $1.3 trillion platform scale to source, negotiate, and execute investments.

Is Blackstone Multi-Asset Investing a public or private company?

Blackstone Multi-Asset Investing is a public company. It is classified as public and is currently operating.

When was Blackstone Multi-Asset Investing founded?

Blackstone Multi-Asset Investing was founded in 1985.

Who are Blackstone Multi-Asset Investing's main competitors?

Direct peers on record are Millennium Management, Man Group, Bridgewater Associates and AQR Capital Management. Broad incumbents are BlackRock, Goldman Sachs Asset Management, Apollo Global Management, JPMorgan Asset Management, KKR & Co. and Carlyle Group.

Does Blackstone Multi-Asset Investing have an API?

No public API is recorded for Blackstone Multi-Asset Investing.

What industry is Blackstone Multi-Asset Investing in?

Blackstone Multi-Asset Investing's product category is Alternative Asset Management. Its primary akta.pro industry code is FSANACAD, Business Services (B2B) Growth Equity, with a secondary code of FSAHAGAD, Securitized Products & Mortgage Credit (RMBS/CMBS/Non-Agency). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceAvere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001Avere Therapeutics announced a $500 million private placement from a syndicate of healthcare investors, adding to a previously announced $320 million concurrent placement. The combined proceeds will fully fund Avere's operating plan into 2029 and support development of its lead program AVR-001. The company is also in an all-stock merger with NextCure, expected to close in the second half of 2026.MorningstarAvere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001Avere Therapeutics announced a $500 million private placement from a syndicate of healthcare investors, adding to a previously announced $320 million concurrent placement. The combined proceeds will fund operations through 2029 and support development of AVR-001, a once-weekly oral IL-23 antagonist. The company is also advancing an all-stock merger with NextCure, expected in the second half of 2026.BioSpaceSynlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private PlacementSynlogic and Caldera Therapeutics announced a merger agreement to combine in an all-stock transaction, with the combined company operating as Caldera Therapeutics. Caldera secured a concurrent private placement of approximately $278 million to fund Phase 2 clinical trials, with cash runway projected into 2029. The deal is expected to close by early 2027.BioSpaceMentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention PipelineMentari Therapeutics announced a $200 million private placement to leading healthcare investors, with proceeds extending cash runway into 2029 and supporting Phase 2a readouts on its PACAP-targeted lead programs. The financing is expected to close before the merger with InMed Pharmaceuticals, which will continue operating under the Mentari name.Clinical Trials ArenaOllin Biosciences secures $330m to fund Phase III OLN324 trialsOllin Biosciences raised $330m in a Series B round to fund global Phase III trials of OLN324 for diabetic macular oedema and wet AMD. The company plans to launch the trials in the second half of 2026, with proceeds also supporting OLN102 development. The financing was oversubscribed and co-led by TCGX and ARCH Venture Partners.Venture Capital Access OnlineOllin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026Ollin Biosciences announced an oversubscribed $330 million Series B financing co-led by TCGX and ARCH Venture Partners. Proceeds will fund global Phase 3 trials of OLN324, a VEGF/Ang2 bispecific antibody, in diabetic macular edema and wet AMD, with trials planned for the second half of 2026.BioSpaceOllin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026Ollin Biosciences announced an oversubscribed $330 million Series B financing co-led by TCGX and ARCH Venture Partners. Proceeds will fund global Phase 3 trials of OLN324 in DME and wet AMD, with studies starting in the second half of 2026. The company also plans to advance OLN102 for thyroid eye disease into clinical development this year.FinSMEsOllin Biosciences Raises $330M in Series B FundingOllin Biosciences raised $330M in Series B funding co-led by TCGX and ARCH Venture Partners. The company will use the funds to support global Phase 3 trials of OLN324, a VEGF/Ang2 antibody for vision-threatening diseases. The JADE study showed OLN324 improved retinal anatomy in diabetic macular edema and wet AMD.MorningstarOllin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026Ollin Biosciences announced an oversubscribed $330 million Series B financing co-led by TCGX and ARCH Venture Partners. Proceeds will support global Phase 3 trials of OLN324 in DME and wet AMD, with studies starting in the second half of 2026. The company also plans to advance OLN102 into clinical development this year.BioSpaceRallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private PlacementRallybio and Avenzo announced a merger agreement to combine into Avenzo Therapeutics, trading as AVZO on Nasdaq. A concurrent oversubscribed private placement of $215 million will fund operations into late 2028. The deal is expected to close in Q4 2026, subject to stockholder approvals and SEC registration.